GILD
$144.40
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Intraday
Recent News
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push
Gilead Sciences (NASDAQ:GILD) executives outlined the company’s approach to next-generation HIV medicines, ongoing commercialization efforts in liver disease, and a broad slate of oncology and inflammation programs during a discussion hosted by Leerink Partners analyst Daina Graybosch. HIV: Moving
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades
Gilead Sciences Inc. (NASDAQ:GILD) is one of Goldman Sachs top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings-per-share growth and margin-expansion prospects as part of its bullish thesis. According to the research firm, […]